ArticleCancer medicine2021
Stage-dependent conditional survival and failure hazard of non-metastatic nasopharyngeal carcinoma after intensity-modulated radiation therapy: Clinical implications for treatment strategies and surveillance.
Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Artificial intelligence-assisted real-time nasopharyngeal cancer diagnostic model enhances rhinologist performance: a prospective multi-reader study.Annals of medicine · 2026Article
- Recent Advances in Surveillance Strategies for Nasopharyngeal Carcinoma.Current oncology reports · 2026Review
- Dynamic disease progression in non-metastatic nasopharyngeal carcinoma post-radical radiotherapy: a Markov model-based analysis in a Chinese cohort.Therapeutic advances in medical oncology · 2026Article
- Article
- Real-time artificial intelligence-assisted detection and segmentation of nasopharyngeal carcinoma using multimodal endoscopic data: a multi-center, prospective study.EClinicalMedicine · 2025Article
- Recent advances in early detection of nasopharyngeal carcinoma.Discover oncology · 2024Review
- Evidence of being cured for nasopharyngeal carcinoma: results of a multicenter patient-based study in China.The Lancet regional health. Western Pacific · 2024Article
- Tumor differentiation-dependent conditional survival of patients with operable thyroid cancer.Frontiers in endocrinology · 2024Article
- Dynamic estimates of survival in oncocytic cell carcinoma of the thyroid.Discover oncology · 2023Article
- Conditional survival nomogram for monitoring real-time survival of young non-metastatic nasopharyngeal cancer survivors.Journal of cancer research and clinical oncology · 2023Article
- A novel conditional survival nomogram for monitoring real-time prognosis of non-metastatic triple-negative breast cancer.Frontiers in endocrinology · 2023Article
- Development and validation of a risk prediction model for overall survival in patients with nasopharyngeal carcinoma: a prospective cohort study in China.Cancer cell international · 2022Article
- Conditional survival analysis and real-time prognosis prediction for cervical cancer patients below the age of 65 years.Frontiers in oncology · 2022Article
- Spatial architecture of regulatory T-cells correlates with disease progression in patients with nasopharyngeal cancer.Frontiers in immunology · 2022Article
- Conditional survival nomogram predicting real-time prognosis of locally advanced breast cancer: Analysis of population-based cohort with external validation.Frontiers in public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeConditional survival (CS) and failure hazard estimations can provide important dynamic prognostic information for clinical decision-making and surveillance counseling. The current study aimed to investigate the CS and dynamic failure hazard in non-metastatic nasopharyngeal carcinoma (NPC) treated with intensity-modulated radiotherapy (IMRT).
methodsConditional overall survival (COS) and progression-free survival (CPFS) estimates adjusted for age and gender against each AJCC 8th stage were calculated. Multivariable Cox regression (MCR) models were fitted in the entire population at baseline and subsequently separate MCR models were fitted in patients who have maintained event-free time of 1 to 10 years to generate respective hazard ratio (HR). Annual hazard rates of death and progression over 10 years for each stage were also estimated.
resultsA total of 1993 patients were eligible for analysis. The estimated 5-year OS and PFS for entire cohort were 79.0% and 70.7% at initial diagnosis. After 5 years of event-free follow-up, additional 5-year COS and CPFS increased to 85.9% and 85.5%, respectively. Stage I/II maintained dramatically favorable CS and low hazard (< 5%) of death and progression over time. Relative to stage I/II, stage III manifested non-significantly higher failure hazard for the first 3 years of survivorship and approached to similar level of stage I/II afterwards. Stage IVA presented most impressive improvement in terms of both COS (∆=9.8%) and CPFS (∆ = 16.8%) whereas still drastically inferior to that of stage I-III across all conditional time points. After 4 years of follow-up, progression hazard of stage IVA became relatively steady of approximate 6%.
conclusionsSurvival prospect of non-metastatic NPC improves over years with distinct dynamic patterns across stages, providing important implications for personalized decision-making in terms of both clinical management and surveillance counseling. Stage-dependent and hazard-adapted clinical management and surveillance are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.